Abstract:
Objective This study evaluates the effect of progesterone on metastatic breast cancer resistant to aromatase inhibitors.
Methods The epidemio-clinical records (i.e., clinical effects, influencing factors, and difference between medroxyprogesterone and megestrol) of metastatic breast cancer patients resistant to aromatase inhibitors and those who underwent progesterone therapy were an- alyzed retrospectively.
Results The clinical benefit rate of progesterone was 21.8 %, and the median progression free survival (PFS). (P = 0.737). Even if the third generation aromatase irLhibitors were not benefited, 22, B % of the patients obtained a benefit through pro- gesterone therapy. Moreover, no difference was observed between the effects of medroxyprogesterone and megestrol in response rate, clinical benefit rate, and PFS (P = 0.595; P = 0.737; P = 0.664). Cox regression showed that the PFS of progesterone was not associat- ed with pathological type, lymph node metastatic status, age, estrogen/progesterone receptor status, Her-2 status, or adjuvant therapy.
Conclusions Progesterone is a good choice of treatment for metastatic breast cancer patients resistant to aromatase inhibitors.